Brian Markison, CEO Evergreen Theragnostics is expected to add Octevy, a registrational stage PET radiodiagnostic that would complement Lantheus' therapeutic candidate, PNT2003. Both acquisitions ...

Reports Q4 revenue $391.1M, consensus $376.18M. “2024 was a groundbreaking year for Lantheus (LNTH), as our radiodiagnostic, PYLARIFY, reached blockbuster status, and we enhanced our ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Lantheus wasn’t one of them. The 10 stocks that made the cut ...

View Our Latest Report on Lantheus Lantheus Stock Performance Shares of Lantheus stock opened at $78.23 on Friday. The firm has a market cap of $5.44 billion, a PE ratio of 13.02 and a beta of 0. ...